Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (RMD) is a health technology company focused on sleep, breathing, and care delivered in the home, and its news flow reflects that focus. Company announcements regularly describe how ResMed creates life-changing health technologies, combining AI-powered digital health solutions, cloud-connected devices, and intelligent software to support sleep and breathing therapy for people in more than 140 countries.
Investors following RMD news can expect updates on financial performance and capital returns, including quarterly earnings releases, dividend declarations, and details of investor webcasts. ResMed frequently issues press releases about its results of operations, margins, cash flow, and related board decisions such as quarterly cash dividends, as documented in its Form 8-K filings and Globe Newswire announcements.
ResMed’s news also highlights product and technology developments. Recent communications include FDA clearance for Smart Comfort, an AI-enabled digital medical device that recommends personalized comfort settings for CPAP therapy, and design awards for the AirTouch N30i nasal cradle mask. These stories often emphasize the use of real-world sleep data, machine learning, and human-centered design to improve comfort and adherence for people with obstructive sleep apnea.
Another recurring theme in ResMed’s news is research and clinical insights. The company has announced landmark studies in The Lancet Respiratory Medicine projecting future obstructive sleep apnea prevalence, as well as meta-analyses on CPAP therapy and mortality. It has also launched initiatives like Sleep Institute to publish evidence-based insights that inform care models and policy discussions around sleep health.
Corporate governance and investor-relations events appear frequently in RMD news as well, including participation in major healthcare conferences, updates on board composition, and details of annual meetings. For readers and investors, the RMD news page offers a centralized view of ResMed’s earnings, product clearances, research publications, and strategic initiatives related to sleep and breathing health.
ResMed (NYSE: RMD) has appointed Mick Farrell as the new chair of the board, effective January 25, 2023. Farrell, who has been CEO since March 2013, succeeds Peter Farrell, who will transition to chair emeritus but remain on the board. Under Mick's leadership, ResMed's market capitalization surged from $6 billion to over $30 billion, achieving a total shareholder return of 507% over the past decade. The board believes combining the CEO and chair roles will enhance efficiency and align with practices of many S&P 500 peers. The company aims to positively impact 250 million lives by 2025.
ResMed reported a 16% year-over-year revenue growth for Q2 2023, totaling $1,033.7 million. This growth was driven by strong demand for sleep and respiratory care devices and an increase of 20% on a constant currency basis. Operating income also increased by 13%, while non-GAAP operating profit rose by 14%. The company achieved a diluted EPS of $1.53 and a non-GAAP diluted EPS of $1.66, reflecting a 13% increase from the previous year. ResMed completed the acquisition of MEDIFOX DAN, enhancing its Software-as-a-Service (SaaS) offerings in Europe. A quarterly cash dividend of $0.44 per share was declared, payable on March 16, 2023.
ResMed (NYSE: RMD) will release its financial and operational results for Q2 FY2023 on January 26, 2023, after NYSE closure. A webcast will follow to discuss these results, starting at 1:30 p.m. PDT (4:30 p.m. EDT). The event will also cover additional forward-looking and material information. Investors can access the webcast at ResMed's investor website. A replay will be available two hours post-webcast, along with a phone replay until February 9, 2023.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PST in San Francisco. The company is known for its innovative solutions aimed at treating chronic diseases like sleep apnea and COPD, enhancing patients' quality of life through digital health technologies. Investors can access the live audio-only webcast and a replay will be available post-event for 30 days. ResMed operates in over 140 countries, focusing on out-of-hospital support systems.
ResMed has acquired MEDIFOX DAN, a leading German software solutions provider, for €958.6 million ($997.5 million). This strategic acquisition marks ResMed's first expansion of its SaaS business into Germany, the second largest healthcare market globally. MEDIFOX DAN will enhance ResMed's portfolio with outpatient therapy service offerings, and its operations will integrate within ResMed's SaaS segment. The acquisition is expected to be accretive to non-GAAP diluted earnings per share, while ResMed plans to retain all MEDIFOX DAN employees and maintain its current brand.
ResMed (NYSE: RMD) reported a 5% year-over-year revenue growth for Q1 2023, totaling $950.3 million, with a 9% increase on a constant currency basis. Operating profit rose 5%, while non-GAAP operating profit increased 4%. Diluted earnings per share increased to $1.43, with a non-GAAP EPS of $1.51. The company noted strong sales in the Americas and expanding gross margins despite increased SG&A expenses. Additionally, ResMed announced the acquisition of mementor and unveiled plans to double its R&D workforce in Ireland.
ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bank of America Global Healthcare Conference on September 14, 2022, at 9:05 a.m. BST in London. This event will be accessible via a live webcast, with a replay available approximately three hours after the event until December 13, 2022. ResMed continues to innovate with digital health technologies and cloud-connected medical devices, aiming to enhance the quality of life for patients suffering from chronic diseases globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET in New York City. The event will include a live webcast, with a replay available three hours after it concludes, accessible until March 11, 2023. ResMed focuses on innovative solutions for chronic diseases, aiming to improve quality of life and reduce healthcare costs globally.
ResMed's latest research reveals that over 480 million people globally suffer from chronic obstructive pulmonary disease (COPD), a prevalence significantly higher—by 22–126%—than previous estimates. This figure could escalate to 592 million by 2050 if current trends in smoking and air pollution continue. COPD costs the EU approximately €48.4 billion annually, with the U.S. facing over $3 billion in hospitalization costs alone. The study urges immediate action for better screening and treatment, stressing the importance of reducing risk factors associated with COPD.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
